Repligen (NASDAQ:RGEN) Stock Crosses Above 50 Day Moving Average – What’s Next?

Repligen Corporation (NASDAQ:RGEN) shares passed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $177.37 and traded as high as $181.46. Repligen shares last traded at $180.17, with a volume of 1,177,395 shares traded.

Key Repligen News

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Repligen reported third-quarter revenue of approximately $209.3 million, up 10.9% year over year and above the $206.7 million analyst consensus. Adjusted earnings of $0.53 per share also exceeded the $0.46 estimate. Repligen Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Management raised 2026 revenue guidance to approximately $844 million-$852 million, representing reported growth of roughly 14.5%-15.5%. The completed BioLife acquisition is expected to strengthen Repligen’s position in the growing cell-therapy market. Repligen Exceeds Q3 Expectations
• Neutral Sentiment: The quarter included a $41.2 million impairment charge, turning reported quarterly profit into a loss. Because the charge is non-cash, investors appear to be placing greater emphasis on adjusted earnings and operating results, but it remains a headwind for GAAP results. Repligen Takes $41.2 Million Impairment Charge
• Negative Sentiment: Filtration revenue declined year over year, and management said some anticipated system deliveries have shifted into 2027. That delay raises concerns about near-term growth momentum despite strength in Proteins, Chromatography and Analytics. Repligen Slips as Investors Weigh Filtration Weakness

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Benchmark raised shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a report on Tuesday, July 7th. JPMorgan Chase & Co. boosted their price target on shares of Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. UBS Group reaffirmed a “buy” rating on shares of Repligen in a research note on Tuesday, September 29th. Barclays raised their price objective on shares of Repligen from $175.00 to $225.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Finally, Canaccord Genuity Group lifted their target price on shares of Repligen from $145.00 to $180.00 and gave the company a “hold” rating in a research note on Monday, October 19th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $178.57.

Repligen Trading Up 5.1%

The company’s 50-day moving average is $177.88 and its 200-day moving average is $145.08. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The firm has a market cap of $10.42 billion, a price-to-earnings ratio of 253.00, a P/E/G ratio of 3.23 and a beta of 1.08.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.07. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm had revenue of $209.31 million during the quarter, compared to analysts’ expectations of $206.71 million. During the same quarter last year, the company posted $0.46 EPS. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. On average, research analysts predict that Repligen Corporation will post 2.06 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RGEN. United Capital Financial Advisors LLC bought a new position in Repligen in the 2nd quarter valued at $380,756,000. Wasatch Advisors LP raised its position in shares of Repligen by 27.9% during the second quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock worth $216,974,000 after acquiring an additional 346,720 shares during the last quarter. Maverick Capital Ltd. bought a new stake in shares of Repligen during the first quarter worth $178,946,000. Conestoga Capital Advisors LLC raised its position in shares of Repligen by 3.8% during the first quarter. Conestoga Capital Advisors LLC now owns 1,097,783 shares of the biotechnology company’s stock worth $129,341,000 after acquiring an additional 39,808 shares during the last quarter. Finally, Congress Asset Management Co. lifted its stake in shares of Repligen by 0.9% during the third quarter. Congress Asset Management Co. now owns 1,020,907 shares of the biotechnology company’s stock valued at $196,249,000 after acquiring an additional 8,681 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.